# Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

> **NCT02508337** · PHASE3 · COMPLETED · sponsor: **Xigen SA** · enrollment: 309 (actual)

## Conditions studied

- Inflammation
- Pain
- Cataract

## Interventions

- **DRUG:** XG-102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02508337
- **Lead sponsor:** Xigen SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-01
- **Final completion:** 2016-03
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508337, "Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02508337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*